Testing a new stronger TB retreatment medicine schedule
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent pulmonary TB that is smear-positive
- You can be an adult or a child (no age limit)
- You can and agree to sign a written consent form (or have a guardian consent if needed)
- For this added group: you live within 5 km of a health facility with a doctor
- Your TB test does not show initial rifampicin resistance on Xpert MTB/RIF
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.